Federal News Update: Federal Shutdown Impacts NIH Operations as FDA Targets Trial Reporting Gaps
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC welcomes three new members
The Association of Multisite Research Corporations (AMRC) today announced the addition of three new members,Rovia Clinical Research, K2 Medical Research, and Eximia, further expanding its representation of leading multisite research organizations across the United States and internationally.
Clinical Trials Sector Braces for Wave of M&A
When Headlands Research was acquired by THL Partners earlier this year, the deal sent a clear signal: consolidation in the clinical trials sector is accelerating. Investors are taking a hard look at the potential of site networks and multisite clinical research corporations (MCRCs) to deliver the scale, quality, and efficiency demanded by sponsors, CROs, and patients.
From headwinds to tailwinds: what can we expect for the rest of 2025 in clinical trials?
There’s an ancient Chinese expression that says, “may you live in interesting times.” For the clinical trial industry, the word “interesting” doesn’t even begin to cover the roller-coaster ride of regulatory changes, disappearing grants, and general uncertainty it’s endured over the past six to twelve months.
Federal News Update: Major CDC Shakeup, FY26 Funding, and New Trial Access Bill
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal News Update: NIH Funding, Vaccine Policy and Looming Drug Pricing Deadline
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC Launches “Access Granted”
Access Granted is the Association of Multisite Research Corporations’s (AMRC) initiative for increasing site participation at industry events. This month, we are giving away five free tickets to the inaugural Partnerships with Sites Summit, 15 September 2025, Philadelphia by entering our free prize giveaway.
AMRC Federal Update, 6-24-25
The Association of Multisite Research Corporations (AMRC), the leading trade association representing multisite clinical research corporations (MCRCs), announces Jennifer Byrne, CEO of Javara, as its newest member of the Board of Directors.
Jennifer Byrne joins AMRC Board of Directors
The Association of Multisite Research Corporations (AMRC), the leading trade association representing multisite clinical research corporations (MCRCs), announces Jennifer Byrne, CEO of Javara, as its newest member of the Board of Directors.
As Pharma Pricing Pressures Hit All-Time High, MCRCs are Uniquely Positioned to Help
The word ‘bipartisan’ might have been sparsely used since January, but the issue of drug pricing has permeated both sides of the aisle over the last three years. The Biden Administration’s Inflation Reduction Act of 2022 marked a policy shift that empowered Medicare to re-negotiate pricing on some high-cost drugs for the first time. The Trump administration also signalled its stance on the issue last week, introducing a ‘Most Favored Nation’ (MFN) pricing model by way of executive order.
